Last-ditch efforts fail to stop medical device tax

The tax has come into force despite opposition by the medical device industry and many politicians.

A tax on medical device sales has come into force after a last-ditch effort to extend the suspension fell short. The failure to stop the progress of the tax means manufacturers will have to report sales to the Internal Revenue Service (IRS) and pay 2.3% on revenues generated by products covered by the levy.

Lawmakers originally came up with the tax to help fund the cost of Obamacare. The industry opposed the tax from day one. And, while it failed to get the tax repealed, it did succeed in pushing back its implementation by two years. That moratorium on the tax ended on 1 January.

The tax has come into force despite opposition by the medical device industry and many politicians. Republican attempts to repeal Obamacare would have eliminated the tax had they succeeded. When the repeal effort failed, focus shifted onto the major tax overhaul designed by the Trump administration. That law passed but lacked provisions for freeing medical device manufacturers from the excise tax.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

With the tax bill passing shortly before the end of 2017, the medical device industry and its friends in Congress embarked on a last-ditch effort to extend the suspension. AdvaMed CEO Scott Whitaker wrote a letter (PDF) to President Donald Trump, in which he called for action to stop a “devastating tax” that has “resulted in the loss or deferred creation of jobs, reduced R&D and slowed capital expansion.”

Whitaker’s preferred option was legislative action to repeal the medical device tax—and he praised lawmakers who proposed such a change in a separate statement—but he also suggested Trump encourage the IRS to provide administrative relief. Such relief could free companies of biweekly deposit requirements that Whitaker thinks lead to “millions in compliance costs.”  

Suggested Articles

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

Novartis tapped Biofourmis to develop tracking programs for heart failure patients, as the latter acquired Biovotion, makers of clinical wearables.

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.